Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Director/PDMR Shareholding

25 Jun 2019 07:00

RNS Number : 2659D
Ergomed plc
25 June 2019
 

Ergomed Plc

("Ergomed" or the "Company")

 

PDMR Dealing

 

Ergomed, a company focused on providing specialised services to the pharmaceutical industry, announces that on 24 June 2019, Dr Miroslav Reljanovic, Executive Chairman of the Company, purchased 200,000 ordinary shares of 1 pence each in the Company ("Share(s)") at a price of 303 pence per Share (the "Purchase").

 

Following the Purchase, Dr Reljanovic's holding in the Company is [11,155,767] Shares (representing [23.97] per cent. of the Company's issued share capital).

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Miroslav Reljanovic

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Purchase of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

303 pence

200,000

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

Volume: 200,000 ordinary shares of 1 pence each, purchase price of 303 pence per share

Aggregated: £606,000.00

 

f)

Date of the transaction

24 June 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHMMGZVMDRGLZZ
Date   Source Headline
16th Nov 20167:00 amRNSResearch Update from Modus Therapeutics
15th Nov 20164:33 pmRNSHolding(s) in Company
1st Nov 20167:00 amRNSCo-Development Agreement with Asarina AB
24th Oct 20167:00 amRNSErgomed notes news from co-development partner
14th Oct 20167:00 amRNSFourth licensing agreement for Zoptrex
26th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSContract win validates rationale of acquisitions
16th Sep 201610:56 amRNSErgomed receives a "buy" recommendation
8th Sep 20167:00 amRNSRecruitment completed in phase IIa clinical trial
7th Sep 201611:30 amRNSNotice of Results
2nd Sep 20167:00 amRNSCo-development partner announces licensing deals
15th Aug 20167:01 amRNSChange of Nominated Adviser
15th Aug 20167:00 amRNSDisclosure of Directors' Appointments
27th Jun 20161:55 pmRNSResult of AGM
27th Jun 20167:00 amRNSUS expansion and opening of office in Boston
20th Jun 20165:49 pmRNSNotice of AGM
14th Jun 201611:49 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAcquisition
6th Jun 20163:31 pmRNSHolding(s) in Company
31st May 20164:45 pmRNSTotal Voting Rights
25th May 201611:55 amRNSHolding(s) in Company
23rd May 201611:10 amRNSResult of Meeting
16th May 20167:00 amRNSPlacing Update
4th May 201612:30 pmRNSProposed acquisition of Haemostatix Limited
30th Mar 201612:00 pmRNSNotice of Results
1st Feb 20161:42 pmRNSHolding(s) in Company
1st Feb 20167:00 amRNSTrading Statement
11th Jan 20167:02 amRNSErgomed Award of Share Options to Director
11th Jan 20167:00 amRNSErgomed announces Board changes
24th Dec 20157:00 amRNSErgomed Awards Share Options
17th Dec 20157:00 amRNSHolding(s) in Company
16th Dec 20157:00 amRNSErgomed Update on Co-Development Partnerships
5th Nov 20157:00 amRNSHolding(s) in Company
29th Oct 201510:00 amRNSErgomed plc to present at German Equity Forum 2015
21st Oct 20159:21 amRNSErgomed Co-Development Partner News
14th Oct 20157:00 amRNSErgomed's Co-Development Partner News
13th Oct 20157:00 amRNSErgomed and Dilaforette Initiate Phase II
5th Oct 20151:09 pmRNSErgomed expands co-development with CEL-SCI
29th Sep 20157:01 amRNSErgomed Interim Results 2015
23rd Sep 20158:00 amRNSErgomed shortlisted for Leading Industry Award
15th Sep 20157:00 amRNSNotice of Results
14th Aug 20157:00 amRNSCo-development partner news
21st Jul 20152:30 pmRNSHolding(s) in Company
20th Jul 20154:20 pmRNSSecondary Placing Of Ordinary Shares in Ergomed
14th Jul 20159:56 amRNSCo-development partner news
10th Jul 20157:00 amRNSAppointment of Director - additional information
2nd Jul 20157:00 amRNSErgomed Strengthens Management Team & Board
30th Jun 201512:43 pmRNSCo-development partner news
25th Jun 20151:06 pmRNSCo-development partner news
19th Jun 201512:35 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.